Tag: ORR
Ichnos Glenmark Innovation’s drug for relapsed multiple myeloma demonstrates postive tolerability...
Company's first presentation of data from Phase 1 study of the Trispecific ISB 2001 showed an overall response rate (ORR) of 75% in Relapsed/Refractory Multiple Myeloma